Methods for a predictive diagnostic test for tamoxifen
OwnerDavid L. Rimm, Jennifer M. Giltnane +1inventors
InventorsDavid L. Rimm, Jennifer M. Giltnane, Lisa Ryden
Life of this patent
Estimating the term…
Abstract
A method for determining the likelihood that a therapy involving administration of tamoxifen to a patient afflicted with an estrogen receptor positive breast cancer will provide a therapeutic benefit to the patient which comprises determining the level of expression of epidermal growth factor receptor present within a non-nuclear compartment in cells present in a breast tissue sample from the patient; and comparing the level of expression so obtained to a predetermined level of expression wherein the likelihood the therapy will provide a therapeutic benefit to the patient is greater if the level of expression in step a) is less than the predetermined level of expression.
Claims25
A method for determining the likelihood that a therapy involving administration of tamoxifen to a patient afflicted with a breast cancer will provide a therapeutic benefit to the patient which comprises:
- a) determining the level of expression of epidermal growth factor receptor in a breast tissue sample from the patient;
- and
- b) comparing the level of expression so obtained to a predetermined reference level of expression of epidermal growth factor receptor in breast cancer tissue samples of patients who had a lack of therapeutic benefit from such a therapy;
- wherein there is a likelihood the therapy will provide the therapeutic benefit to the patient if the level of expression determined in step a) is less than the predetermined reference level of expression.
A method for identifying a patient afflicted with a breast cancer who will likely obtain a therapeutic benefit from tamoxifen therapy which comprises:
- a) determining the level of expression of epidermal growth factor receptor in a breast tissue sample from the patient;
- and
- b) comparing the level of expression so obtained to a predetermined reference level of expression of epidermal growth factor receptor in breast cancer tissue samples of patients who had a lack of therapeutic benefit from such a therapy;
- wherein the patient will likely obtain the therapeutic benefit from tamoxifen therapy if the level of expression determined in step a) is less than the predetermined reference level of expression.
17-22. (canceled)
(canceled)
A method for determining whether a breast cancer will be responsive to tamoxifen therapy which comprises:
- a) determining the level of expression of epidermal growth factor receptor in a breast tissue sample from the patient;
- and
- b) comparing the level of expression so obtained to a predetermined reference level of expression of epidermal growth factor receptor in breast cancer tissue samples of patients who had a lack of therapeutic benefit from such a therapy;
- wherein the breast cancer will be responsive to tamoxifen if the level of expression determined in step a) is less than the predetermined reference level of expression.
26-36. (canceled)
A method for determining whether a breast cancer will not be responsive to tamoxifen therapy which comprises:
- a) determining the level of expression of epidermal growth factor receptor in a breast tissue sample from the patient;
- and
- b) comparing the level of expression so obtained to a predetermined reference level of expression of epidermal growth factor receptor in breast cancer tissue samples of patients who had a lack of therapeutic benefit from such a therapy;
- wherein the breast cancer will be not responsive to tamoxifen therapy if the level of expression determined in step a) is greater than the predetermined reference level of expression.
38-48. (canceled)
A method for determining the likelihood that a therapy involving administration of an aromatase inhibitor to a patient afflicted with a breast cancer will provide a therapeutic benefit to the patient which comprises:
- a) determining the level of expression of epidermal growth factor receptor in a breast tissue sample from the patient;
- and
- b) comparing the level of expression so obtained to a predetermined reference level of expression of epidermal growth factor receptor in breast cancer tissue samples of patients who had a lack of therapeutic benefit from such a therapy;
- wherein there is a likelihood the therapy will provide the therapeutic benefit to the patient if the level of expression determined in step a) is less than the predetermined reference level of expression.
50-61. (canceled)
Dependencies are inferred from the claim text.